PMID- 36439091
OWN - NLM
STAT- MEDLINE
DCOM- 20221130
LR  - 20221130
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin 
      lymphoma: A meta-analysis of prospective clinical trials.
PG  - 1034253
LID - 10.3389/fimmu.2022.1034253 [doi]
LID - 1034253
AB  - BACKGROUND: Copanlisib is an intravenously administered pan-class I PI3K 
      inhibitor that has been demonstrated to have appreciable effects in the treatment 
      of patients with lymphoma. The purpose of this meta-analysis was to evaluate the 
      efficacy and safety of copanlisib for treating patients with relapsed/refractory 
      (R/R) B-cell non-Hodgkin lymphoma (B-NHL). METHODS: PubMed, Web of Science, 
      EMBASE, and the Cochrane Central Register of Controlled Trials were searched for 
      relevant studies published prior to July 2022. The efficacy evaluation included 
      complete response rate (CR), partial response rate (PR), rate of stable disease 
      (SDR), overall response rate (ORR), disease control rate (DCR), rate of 
      progressive disease (PDR), median progression-free survival (PFS), and median 
      overall survival (OS). Any grade adverse events (AEs) and grade >/=3 AEs were 
      synthesized to assess its safety. RESULTS: Eight studies with a total of 652 
      patients with R/R B-NHL were identified. The pooled CR, PR, ORR, SDR, DCR, and 
      PDR from all 8 articles were 13%, 40%, 57%, 19%, 86%, and 9%, respectively. The 
      CR and ORR of combination therapy with rituximab were higher than those with 
      copanlisib monotherapy for R/R B-NHL (34% vs. 6%, p<0.01; 89% vs. 42%, p<0.01). 
      For patients with R/R indolent B-NHL, CR and ORR were lower with copanlisib 
      monotherapy than with combination therapy with rituximab (7% vs. 34%, p<0.01; 58% 
      vs. 92%, p<0.01). In R/R B-NHL patients receiving copanlisib monotherapy and 
      combination therapy with rituximab, the risk of any grade AEs was 99% and 96%, 
      respectively, and the risk of grade >/=3 AEs was 84% and 91%, respectively. The 
      common any grade AEs included hyperglycemia (66.75%), hypertension (48.57%), 
      diarrhea (35.06%), nausea (34.98%) and fatigue (30.33%). The common grade >/=3 AEs 
      included hyperglycemia (45.14%), hypertension (35.07%), and neutropenia (14.75%). 
      The comparison of AEs between the copanlisib monotherapy and the combination 
      therapy with rituximab showed that hyperglycemia of any grade (p<0.0001), 
      hypertension of any grade (p=0.0368), fatigue of any grade (p<0.0001), grade >/=3 
      hypertension (p<0.0001) and grade >/=3 hyperglycemia (p=0.0074) were significantly 
      different between the two groups. CONCLUSION: Our meta-analysis demonstrated that 
      the efficacy of both copanlisib monotherapy and combination therapy with 
      rituximab in patients with R/R B-NHL was satisfactory, while treatment-related 
      AEs were tolerable. Compared with copanlisib monotherapy, combination therapy 
      with rituximab showed superior efficacy for treating R/R B-NHL, and its safety 
      was manageable. SYSTEMATIC REVIEW REGISTRATION: 
      https://inplasy.com/inplasy-2022-10-0008/, identifier INPLASY2022100008.
CI  - Copyright (c) 2022 Wang, Zhou, Mu, Zhao, Cai, Li, Wang and Niu.
FAU - Wang, Jinjin
AU  - Wang J
AD  - Department of Hematology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Zhou, Hui
AU  - Zhou H
AD  - Department of Hematology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Mu, Mingchun
AU  - Mu M
AD  - Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 
      China.
FAU - Zhao, Ailin
AU  - Zhao A
AD  - Department of Hematology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Cai, Zhaolun
AU  - Cai Z
AD  - Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 
      China.
FAU - Li, Linfeng
AU  - Li L
AD  - Department of Hematology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Wang, Mengyao
AU  - Wang M
AD  - Department of Hematology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Niu, Ting
AU  - Niu T
AD  - Department of Hematology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
LA  - eng
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20221111
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - WI6V529FZ9 (copanlisib)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - Fatigue
MH  - Hyperglycemia
MH  - Hypertension
MH  - *Lymphoma, B-Cell/drug therapy
MH  - Prospective Studies
MH  - Rituximab/therapeutic use
MH  - *Neoplasm Recurrence, Local/drug therapy
MH  - *Phosphoinositide-3 Kinase Inhibitors/adverse effects
PMC - PMC9691663
OTO - NOTNLM
OT  - R/R B-NHL
OT  - copanlisib
OT  - efficacy
OT  - meta-analysis
OT  - rituximab
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/29 06:00
MHDA- 2022/11/30 06:00
PMCR- 2022/01/01
CRDT- 2022/11/28 04:30
PHST- 2022/09/01 00:00 [received]
PHST- 2022/10/27 00:00 [accepted]
PHST- 2022/11/28 04:30 [entrez]
PHST- 2022/11/29 06:00 [pubmed]
PHST- 2022/11/30 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.1034253 [doi]
PST - epublish
SO  - Front Immunol. 2022 Nov 11;13:1034253. doi: 10.3389/fimmu.2022.1034253. 
      eCollection 2022.